![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 4 of 4. This is the beginning of the thread.
Posted by Jeroen on September 18, 2015, at 15:15:50
FDA Approves Vraylar (cariprazine) for Schizophrenia and Bipolar Disorder
good news! finally
Posted by linkadge on September 18, 2015, at 16:57:53
In reply to FDA Approves Vraylar (cariprazine) for Schizophren, posted by Jeroen on September 18, 2015, at 15:15:50
Hmm. Interesting mechanism. I am eager to hear people's experiences.
Posted by Jeroen on September 20, 2015, at 12:21:37
In reply to Re: FDA Approves Vraylar (cariprazine) for Schizophren, posted by linkadge on September 18, 2015, at 16:57:53
TD, NMS warning on that cariprazine damnid,
Posted by SLS on September 20, 2015, at 14:40:06
In reply to TD, NMS warning on that cariprazine, posted by Jeroen on September 20, 2015, at 12:21:37
> TD, NMS warning on that cariprazine damnid,
I haven't seen the package label for cariprazine yet. However, I believe NMS and TD will be listed as a class effect, even if cariprazine has not yet demonstrated them. Theoretically, NMS and TD are possible with all neuroleptic antipsychotics, including cariprazine. I am hoping that dopamine receptor partial agonists like Abilify are less likely to cause these things. However, I have not seen anything that would indicate this.
- Scott
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.